Sizing up pharmacotherapy for obesity

Clinical and Translational Science

Volumn 3, Issue 3, 2010, Pages 123-125

  Valentino, Michael A ^a   Terzic, Andre ^b   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BETA 3 ADRENERGIC RECEPTOR; DIAZOXIDE; EXENDIN 4; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; LIRAGLUTIDE; LORCASERIN; MATRIX METALLOPROTEINASE; NALTREXONE; NEUROPEPTIDE Y; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; OXYNTOMODULIN; PEPTIDE YY; PRAMLINTIDE; SIBUTRAMINE; SIRTUIN 1; TETRAHYDROLIPSTATIN; ZONISAMIDE; ANTIOBESITY AGENT; BIOGENIC AMINE; HORMONE; NEUROPEPTIDE;

ADIPOCYTE; AEROBIC METABOLISM; ALCOHOL ABUSE; ANGIOGENESIS; APPETITE; ARCUATE NUCLEUS; ARTICLE; BILIARY TRACT DISEASE; BROWN ADIPOSE TISSUE; CELL METABOLISM; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG MECHANISM; ENERGY BALANCE; FOOD AVAILABILITY; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER DISEASE; NAUSEA AND VOMITING; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOARTHRITIS; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SKELETAL MUSCLE; SLEEP APNEA SYNDROME; SMOKING; STROKE; WEIGHT GAIN; WEIGHT REDUCTION; DRUG EFFECT; SYNAPTIC TRANSMISSION;

ANTI-OBESITY AGENTS; BIOGENIC AMINES; HORMONES; HUMANS; LIPOGENESIS; NEUROPEPTIDES; OBESITY; SYNAPTIC TRANSMISSION;

EID: 77957286797     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2010.00191.x     Document Type: Article

References (40)

1. James, WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008; 263: 336-352.
2. Rodgers A, Vaughan P, Prentice T, Edejer TT-T, Evans D, Lowe J. Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002: 1-248.
3. Daniels J. Obesity: America's epidemic. Am J Nurs. 2006; 106: 40-49.
4. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med. 2007; 356: 213-215.
5. Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH, Looker HC. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med. 2010; 362: 485-493.
6. Kopelman P. Health risks associated with overweight and obesity. Obes Rev. 2007; 8 (Suppl 1): 13-17.
7. Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Aff. 2002; 21: 245-253.
8. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007; 121: 492-496.
9. Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? J Am Med Assoc. 1999; 282: 1576-1578.
10. Sarwer DB, von Sydow G A, Vetter M, Wadden TA. Behavior therapy for obesity: where are we now? Curr Opin Endocrinol Diabetes Obes. 2009; 16: 347-352.
11. Perri M, Corsica J. Improving the maintenance of weight lost in behavioral treatment of obesity. In: Wadden T, Stunkard A, eds. Handbook of obesity treatment. 1st ed. New York: Guilford Press; 2002: 357-379.
12. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG Jr, Ozcan U. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009; 9: 35-51.
13. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008; 105: 7257-7262.
14. Amylin Pharmaceuticals, Inc. research pipeline. Available at: http://www.amylin.com/research/pipeline/exenatide-once-weekly.htm. Accessed March 1, 2010.
15. Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue (13 Jan 2010). Available at: http://www.novonordisk.com/press/news/news.asp?sNewsTypeGUID=&lMonth=&lYear=&sLanguageCode=&sSearchText=NN9924&sShowNewsItemGUID=acc555cc-2124-4ebf-ad6d-7f923e2e2a78&sShowLanguageCode=en-GB. Accessed March 1, 2010.
16. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost, GS, Meeran K, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005; 54: 2390-2395.
17. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes. 2006; 30: 1729-1736.
18. Wyeth Pharmaceuticals acquires Thiakis Limited. Available at: http://www.drugs.com/news/wyeth-pharmaceuticals-acquires-thiakis-limited-15289.html. Accessed February 22, 2010.
19. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology. 2005; 129: 1430-1436.
20. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, MacNeil DJ, Heymsfi eld SB, Amatruda JM. Effi cacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab. 2007; 92: 1754-1757.
21. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM, Janda KD. Vaccination against weight gain. Proc Natl Acad Sci U S A. 2006; 103: 13226-13231.
22. Moran TH, Dailey MJ. Gut peptides: targets for antiobesity drug development? Endocrinology. 2009; 150: 2526-2530.
23. Elixir pharmaceuticals product pipeline. Available at: http://www.elixirpharm.com/product/index.html. Accessed February 1, 2010.
24. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfi eld SB. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006; 4: 275-282.
25. Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol. 2009; 68: 852-860.
26. King PJ, Widdowson PS, Doods HN, Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem. 1999; 73: 641-646.
27. 7TM Pharma research pipeline. Available at: http://www.7tm.com/Pipeline.aspx. Accessed February 3, 2010.
28. TransTech Pharma obesity product pipeline. Available at: http://www.ttpharma.com/TherapeuticAreas/MetabolicDiseases/Obesity/TTP435/tabid/126/Default.aspx. Accessed February 3, 2010.
29. Bristol-Myers Squibb metabolics clinical trial registry. Available at: http://ctr.bms.com/OneBmsCtd/ InitTrialAction.do?linkname=Metabolics&type=pharma&sortby=default. Accessed March 10, 2010.
30. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obesity. 2002; 10: 1049-1056.
31. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obesity. 2002; 10: 633-641.
32. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT(2C) receptor gene. Nat Med. 1998; 4: 1152-1156.
33. Lorcaserin for weight management. Available at: http://www.arenapharm.com/wt/page/lho.html. Accessed March 12, 2010.
34. Alemzadeh R, Langley G, Upchurch L, Smith P, Slonim AE. Benefi cial effect of diazoxide in obese hyperinsulinemic adults. J Clin Endocrinol Metab. 1998; 83: 1911-1195.
35. de Souza C.J, Burkey BF. Beta3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001; 7: 1433-1449.
36. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002; 99: 10730-10735.
37. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado de Oliveira R, Leid M, McBurney MW, Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-[gamma]. Nature. 2004; 429: 771-776.
38. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso, M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1[alpha]. Cell. 2006; 127: 1109-1122.
39. Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009; 16: 353-358.
40. + channels control energy expenditure determining body weight. Cell Metab. 2010; 11: 58-69.